A Randomized, Single‐Center, Double‐Blind, Placebo‐Controlled Multiple‐Dose Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Imarikiren in Healthy Adult Nonelderly and Elderly Male Subjects

Imarikiren hydrochloride (TAK‐272/ SCO‐272) is a novel direct renin inhibitor. This randomized, double‐blind, phase I study evaluated the safety and pharmacokinetics/pharmacodynamics of multiple oral administrations of imarikiren in healthy nonelderly (aged 20‐45 years) and elderly (aged 65‐85 years...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuno, Kumi, Tanaka, Shingo, Hashimoto, Takamasa, Nakamichi, Hiroyuki, Kagawa, Tomoya, Koumura, Emiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Pharmacokinetics/Pharmacodynamics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175367/
https://www.ncbi.nlm.nih.gov/pubmed/29733435
http://dx.doi.org/10.1002/jcph.1142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175367/
https://www.ncbi.nlm.nih.gov/pubmed/29733435
http://dx.doi.org/10.1002/jcph.1142

Ejemplares similares